Skip to main navigation Skip to search Skip to main content

I-Corps: Translation Potential of Molecular Discovery with Explainable Artificial Intelligence

Project: Research

Abstract & Details

Description

Award ID: 2501382

This I-Corps project is based on the translation from lab to market of an advanced artificial intelligence (AI) software tool designed to enhance molecular and drug discovery processes. Drug discovery is a crucial aspect of pharmaceutical development, directly impacting human health and the creation of life-saving treatments. Applying an AI tool that generates interpretable explanations for how and why drug candidates were suggested can accelerate the drug discovery process. The commercialization of this technology has the potential to benefit society by reducing the time and cost associated with pharmaceutical research and development, leading to faster drug approvals and broader accessibility to new treatments. With traditional drug development costing over $2 billion and taking 10-15 years, this solution has the potential to accelerate and de-risk drug discovery, making it attractive to pharmaceutical firms and research institutions. This I-Corps project utilizes experiential learning coupled with a first-hand investigation of the industry ecosystem to assess the translation potential of a Graph Neural Network (GNN)-enhanced Explainable software suite for drug discovery. The software integrates GNN-explainers that provide interpretable explanations for the GNN-based model, with extensive molecular datasets to identify functional compounds more efficiently and with greater interpretability than existing AI-driven approaches. The system includes input preparation of diverse chemical and biological datasets to train black-box GNN models. An explainer framework then analyzes the black-box GNNs, developing explanation sub-graphs and identifying graph information bottlenecks through a GNN-enhanced explainable AI approach. The benefits of this approach include improved efficiency in identifying viable drug candidates, reduced computational costs, and enhanced transparency in AI-driven molecular discovery. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

NSF Program Director: Ruth Shuman
StatusActive
Effective start/end date05/15/2504/30/27

Funding

  • I-Corps Teams: $50,000.00

Active Fiscal Year

  • FY2027
  • FY2026
  • FY2025

Start Fiscal Year

  • FY2025

TIP Programs

  • I-Corps Teams

Key Technology Areas

  • Artificial Intelligence
  • (confidence score: 100%)
  • Biotechnology
  • (confidence score: 100%)

Technology Foci

  • Genomics and bioinformatics
  • (confidence score: 100%)
  • Machine Learning Training Data
  • (confidence score: 100%)
  • Machine Learning (ML)
  • (confidence score: 100%)
  • Artificial Intelligence (excluding ML)
  • (confidence score: 85%)

Congressional District at Award

  • District n. 10 of New Jersey

Current Congressional District

  • District n. 10 of New Jersey

United States

  • New Jersey

Core Based Statistical Area (CBSA)

  • New York-Newark-Jersey City, NY-NJ

County

  • County: Essex, NJ

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint. Learn more about Elsevier's Fingerprint Engine here: https://beta.elsevier.com/products/elsevier-fingerprint-engine